Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Accumulated Expenses for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 74.59% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 74.59% decrease, with the full-year FY2025 number at $2.0 million, down 74.59% from a year prior.
  • Other Accumulated Expenses was $2.0 million for Q4 2025 at Beam Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $28.6 million in Q4 2023 to a low of $2.0 million in Q4 2025.
  • A 5-year average of $9.5 million and a median of $7.0 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 212.95% in 2024, then crashed 90.49% in 2025.
  • Beam Therapeutics' Other Accumulated Expenses stood at $7.0 million in 2021, then skyrocketed by 76.08% to $12.3 million in 2022, then skyrocketed by 133.58% to $28.6 million in 2023, then plummeted by 72.73% to $7.8 million in 2024, then tumbled by 74.59% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Other Accumulated Expenses are $2.0 million (Q4 2025), $2.7 million (Q3 2025), and $2.2 million (Q2 2025).